On Monday, in the course of current trade, Shares of Annaly Capital Administration, Inc. (NYSE:NLY), climbed 0.10%, and is now trading at $10.09.
Annaly Capital Administration, declared that its Board of Directors has authorized the repurchase of up to $1 billion of its outstanding common shares through December 31, 2016.
Purchases made following the program will be made in either the open market or in privately negotiated transactions from time to time as permitted by securities laws and other legal requirements. The timing, manner, price and amount of any repurchases will be determined by the Company in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements and other factors. The authorization does not obligate the Company to acquire any particular amount of common shares and the program may be suspended or suspended at the Company’s discretion without preceding notice. The Board will assess the effects of this program at its completion.
Annaly Capital Administration, Inc. owns a portfolio of real estate related investments in the United States. The company invests in various types of agency mortgage-backed securities and related derivatives to hedge these investments; acquires, finances, and manages commercial mortgage loans and other commercial real estate debt, commercial mortgage-backed securities, and other commercial real estate-related assets; and operates as a broker-dealer.
During an Afternoon trade, Shares of CIGNA Corporation (NYSE:CI), dipped -0.34%, and is now trading at $145.39.
Cigna and Virginia Cancer Institute have started a program that aims to enhance care for people receiving chemotherapy to treat any type of cancer.
The program is part of Cigna Collaborative Care, a value-based model that engages health care professionals and assists drive improved health, affordability and patient experience. Cigna Collaborative Care initially focused on large primary care physician groups and has expanded to comprise hospitals, small primary care practices and specialists, counting oncologists.
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The company’s Commercial segment offers insured and self-insured customers medical, dental, behavioral health, and vision, in addition to prescription drug benefit plans, health advocacy programs, and other products and services.
Finally, Perrigo Company plc Ordinary Shares (NYSE:PRGO), gained 1.59% Monday.
Perrigo Company plc, declared results for the second calendar quarter ended June 27, 2015.
Perrigo’s Chairman, President and CEO Joseph C. Papa commented, “The team delivered a strong financial performance in the quarter, record quarterly net sales, etc. Our Branded Consumer Healthcare segment, comprised of our recently attained Omega Pharma assets, achieved an impressive $401 million in sales, which comprised of new product sales of $33 million. With Omega in our portfolio, merged new product sales for Perrigo were a record $149 million. The Rx segment grew 10% in the quarter on top of a record performance last year. Notwithstanding a decline in the VMS and animal health categories, we grew adjusted operating income by 18% to a record $160 million in the Consumer Healthcare segment. Since the closing of the Omega Pharma acquisition, we have continued to execute on a major component of our ‘Base Plus Plus Plus’ strategy, with three declared acquisitions, two of which build upon our pan-European platform. Our durable business model and future growth prospects are self-evident as we continue to progress on our stand-alone strategy.”
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
